Search results
Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
Reuters via Yahoo News· 11 months agoJohnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster...
From Nurse To Patient: My Journey With Crohn’s Disease
Women's Health via Yahoo News· 2 years agoAs a healthcare professional, Alison spent her days doing endoscopies, which are one of the many...
J&J's medical device sales fall short, cancer drugs seen growing
Reuters via Yahoo Finance· 1 week ago(Reuters) -Johnson & Johnson's first-quarter revenue missed Wall Street estimates for medical...
J&J sues Amgen over plan to sell drug similar to blockbuster Stelara
Reuters via Yahoo News· 1 year ago(Reuters) -Johnson & Johnson's Janssen unit has sued Amgen Inc over its plan to market a drug for...
Unexpected drugs make first round of Medicare negotiations
The Hill via Yahoo News· 8 months agoThe Centers for Medicare and Medicaid Services (CMS) have officially named the first 10 drugs chosen...
Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.
Motley Fool via Yahoo Finance· 1 month agoJohnson & Johnson (NYSE: JNJ) is one of the leading and most recognizable names in healthcare. It...
Novartis' Sandoz targets biosimilar version of J&J drug in Samsung deal
Reuters via Yahoo News· 7 months agoFRANKFURT (Reuters) -Novartis' generic-drugs unit Sandoz said on Monday it plans to launch a generic...
U.S. drug price negotiations are underway. Here’s what that will mean for you—eventually
Fortune via Yahoo Finance· 3 months agoNegotiations are underway between the federal government and pharmaceutical companies to determine...
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
Motley Fool via Yahoo Finance· 2 weeks agoJohnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer...
Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts
BioPharma Dive via Yahoo Finance· 2 months agoThe CEOs of three major drugmakers defended the prices they charge U.S. patients in a Senate...